These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

946 related articles for article (PubMed ID: 17214731)

  • 1. Juvenile mycosis fungoides treated with bexarotene and PUVA.
    Rodríguez-Vázquez M; García-Arpa M; González-García J
    Int J Dermatol; 2007 Jan; 46(1):99-102. PubMed ID: 17214731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
    Stern DK; Lebwohl M
    J Drugs Dermatol; 2002 Sep; 1(2):134-6. PubMed ID: 12847736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB.
    D'Acunto C; Gurioli C; Neri I
    J Dermatolog Treat; 2010 Jan; 21(1):45-8. PubMed ID: 19603308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
    Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
    Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of mycosis fungoides with bexarotene and psoralen plus ultraviolet A.
    Coors EA; Von den Driesch P
    Br J Dermatol; 2005 Jun; 152(6):1379-81. PubMed ID: 15949024
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
    Whittaker S; Ortiz P; Dummer R; Ranki A; Hasan B; Meulemans B; Gellrich S; Knobler R; Stadler R; Karrasch M
    Br J Dermatol; 2012 Sep; 167(3):678-87. PubMed ID: 22924950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of a folliculotropic mycosis fungoides with bexarotene and PUVA.
    Krönke A; Schlaak M; Arin M; Mauch C; Kurschat P
    Eur J Dermatol; 2012; 22(2):259-60. PubMed ID: 22240623
    [No Abstract]   [Full Text] [Related]  

  • 8. Full clinical recovery after topical acyclovir treatment of Epstein-Barr virus associated cutaneous B-cell lymphoma in patient with mycosis fungoides.
    Copur MS; Deshpande A; Mleczko K; Norvell M; Hrnicek GJ; Woodward S; Frankforter S; Mandolfo N; Fu K; Chan WC
    Croat Med J; 2005 Jun; 46(3):458-62. PubMed ID: 15861527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
    Kannangara AP; Levitan D; Fleischer AB
    J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Granulomatous mycosis fungoides: combination therapy with bexarotene and PUVA].
    Wirtz M; Helbig D
    Hautarzt; 2014 Apr; 65(4):274-6. PubMed ID: 24671704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycosis fungoides in a hemodialysis patient with intractable pruritus.
    Miyoshi M; Ubara Y; Tagami T; Sawa N; Son D; Hoshino J; Katori H; Takemoto F; Hara S; Kishi A; Motoi N; Takaichi K
    Ther Apher Dial; 2006 Jun; 10(3):296-300. PubMed ID: 16817798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic features and T-cell receptor gene rearrangement findings of mycosis fungoides palmaris et plantaris.
    Kim ST; Jeon YS; Sim HJ; Kim SH; Kim YK; Suh KS; Park JH; Park SW
    J Am Acad Dermatol; 2006 Mar; 54(3):466-71. PubMed ID: 16488298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
    Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
    J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycosis fungoides with depigmentation secondary to treatment.
    Firoz B; Kovich OI; Latkowski JA
    Dermatol Online J; 2007 Jan; 13(1):18. PubMed ID: 17511951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Change of level of mycosis fungoides under systemic PUVA-therapy (author's transl)].
    Tourbier H; Schultz-Ehrenburg U
    Z Hautkr; 1981 Jul; 56(14):923-9. PubMed ID: 7269717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Foreign-body-associated granulomatous slack skin in folliculotropic mycosis fungoides of childhood.
    Tronnier M
    J Cutan Pathol; 2009 May; 36(5):578-81. PubMed ID: 19476528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follicular mycosis fungoides: successful treatment with oral bexarotene.
    Shistik G; Scalf LA; Fenske N; Glass LF
    J Drugs Dermatol; 2004; 3(3):301-4. PubMed ID: 15176165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
    Duvic M; Martin AG; Kim Y; Olsen E; Wood GS; Crowley CA; Yocum RC;
    Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bexarotene plus PUVA plus radiation combination therapy for mycosis fungoides.
    Coors E
    Dermatol Clin; 2008 Jan; 26 Suppl 1():33-5. PubMed ID: 18405185
    [No Abstract]   [Full Text] [Related]  

  • 20. Case experience of 308-nm excimer laser therapy compatibility with PUVA and oral bexarotene for the treatment of cutaneous lesions in mycosis fungoides.
    Huang J; Cowper S; Moss J; Girardi M
    J Drugs Dermatol; 2013 Apr; 12(4):487-9. PubMed ID: 23652902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.